Capitalization 7.36B P/E ratio 2024 *
-13.4x
P/E ratio 2025 * -15.5x
Enterprise value 6.16B EV / Sales 2024 *
11.9x
EV / Sales 2025 * 9.9x
Free-Float
99.17%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day+0.61%
1 week+1.81%
Current month+6.46%
1 month+21.30%
3 months+21.27%
6 months-2.07%
Current year+0.30%
More quotes
1 week
46.58
Extreme 46.58
51.72
1 month
44.35
Extreme 44.345
51.72
Current year
35.95
Extreme 35.95
54.44
1 year
35.95
Extreme 35.95
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Insider TitleAgeSince
Founder 62 89-01-09
Director of Finance/CFO 62 00-04-30
Chief Tech/Sci/R&D Officer - -
Insider TitleAgeSince
Director/Board Member 70 91-10-31
Director/Board Member 79 93-12-31
Director/Board Member 62 05-12-12
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.61%+1.81%+24.82%+33.42% 7.36B
-2.52%-5.55%-6.52%-66.12% 46.47B
-0.02%+2.48%+4.60%-4.15% 43.53B
+0.23%+1.63%+6.46%-25.94% 42.23B
+0.93%-5.34%+18.20%+29.64% 29.64B
+2.22%+2.49%+28.08%-23.59% 28.11B
-0.14%-4.17%+34.90%+52.19% 27.47B
-1.53%+1.04%+33.58%+79.66% 14.94B
+1.44%-2.77%-13.21%-34.56% 12.06B
+0.97%-2.16%+7.77%-43.88% 11.35B
Average +0.49%-1.04%+13.87%-0.33% 26.31B
Weighted average by Cap. +0.43%-0.93%+11.67%-8.28%
See all sector performances
Ratios2024 *2025 *
Net sales 602M 770M
Net income -569M -518M
Net Debt -196M 264M
More financial data * Estimated data
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Employees
927
Calendar
More about the company
Date Price Change Volume
24-07-24 50.74 $ +0.61% 1,664,818
24-07-23 50.43 $ -0.36% 1,385,120
24-07-22 50.61 $ +5.83% 1,791,670
24-07-19 47.82 $ +1.04% 1,090,260
24-07-18 47.33 $ -1.31% 1,133,696

Delayed Quote Nasdaq, July 24, 2024 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
50.43USD
Average target price
60.27USD
Spread / Average Target
+19.51%
Consensus